Novartis and Monte Rosa Therapeutics have entered an expanded research collaboration worth up to $5.7 billion, advancing molecular glue degraders for immune-mediated diseases. This new agreement grants Novartis exclusive licenses and options for multiple preclinical programs, building on their initial Phase II collaboration. Monte Rosa’s AI-based platform, QuEEN, guides the selective targeting and degradation of difficult proteins, positioning both companies at the forefront of protein degradation therapeutics. Novartis’s investment underscores the strategic importance of novel degradation modalities to address high unmet medical needs in immunology.